Table 4 Characterization of subgroups after AKI detection
Total cohort | Disease group | AKI stages | |||||
|---|---|---|---|---|---|---|---|
Characteristic | N = 21045 Median (IQR) / n (%) | AKI N = 13755 Median (IQR) / n (%) | No AKI N = 7290 Median (IQR) / n (%) | p-valuea | AKI 1 N = 3707 Median (IQR) / n (%) | AKI 2 N = 6423 Median (IQR) / n (%) | AKI 3 N = 3625 Median (IQR) / n (%) |
Age at admission | 71 (62, 78) | 72 (63, 78) | 70 (61, 78) | < 0.001 | 72 (63, 78) | 72 (63, 78) | 72 (64, 78) |
Male | 15,048 (72%) | 10,010 (73%) | 5038 (69%) | < 0.001 | 2724 (73%) | 4667 (73%) | 2619 (72%) |
Length ICU stay (day) | 7.8 (5.8, 11.8) | 8.8 (6.1, 12.5) | 6.6 (4.9, 9.4) | < 0.001 | 7.6 (5.9, 11.1) | 8.8 (6.2, 12.1) | 10.1 (6.9, 13.5) |
Number of drugs administered | 18 (13, 24) | 21 (16, 27) | 13 (3, 18) | < 0.001 | 18 (14, 22) | 21 (17, 27) | 24 (18, 34) |
Number of patients receiving nephrotoxic drugs | 1374 (6.5%) | 1097 (8.0%) | 277 (3.8%) | < 0.001 | 200 (5.4%) | 489 (7.6%) | 408 (11%) |
Number of different AKI comorbidities/ risk factors | 2 (0, 3) | 2 (1, 4) | 0 (0, 2) | < 0.001 | 2 (1, 3) | 3 (1, 4) | 3 (1, 4) |